22 completed, 2 terminated, 1 active not recruiting, 1 unknown. 8 Phase 2, 5 Phase 3, 5 Phase 4, 3 Not applicable, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 8 |
| Phase 3 | 5 | Completed 5 |
| Phase 4 | 5 | Completed 3, Active not recruiting 1, Terminated 1 |
| Not applicable | 3 | Completed 3 |
| Phase 1 | 2 | Completed 2 |
Follow Human Influenza: new trials by email Literature Review of Human Influenza trials Research Report on Human Influenza
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Universal Influenza A Vaccine in Healthy Adults UFluA 20 µg each antigen/dose, UFluA 60 µg each antigen/dose, Placebo - Human Influenza | Phase 1 | Completed | Emergent BioSolutions | 27 | 2021-12-01 | 2025-01-20 |
| Tfh Dysfunction in HIV and Aging Standard dose influenza vaccination, High dose influenza vaccination - Human Influenza | Phase 4 | Active not recruiting | University of Miami | 400 | 2020-10-30 | 2026-07-17 |
| Evaluation of a Single Use Point of Care Device for the Diagnosis of Respiratory Pathogens Point of care testing of respiratory viruses. - Human Influenza, Respiratory Syncytial Virus Infections | Terminated | Imperial College London | 6 | 2020-02-21 | 2025-02-13 | |
| Safety of 4Fluart ID Suspension for Injection in Adult Subjects 4Fluart ID suspension for injection study drug 1 µg/0.1 ml, influenza vaccine (whole virion, inactivated, adjuvanted), 4Fluart ID suspension for injection study drug 2 µg/0.1 ml, influenza vaccine (whole virion, inactivated, adjuvanted), 3Fluart suspension for injection, influenza vaccine (whole virion, inactivated, adjuvanted) - Human Influenza | Phase 1 | Completed | Fluart Innovative Vaccine Ltd, Hungary | 36 | 2018-01-31 | 2021-03-03 |
| Preventive Effectiveness, Safety and Immunogenicity of a Allantoic Split Inactivated Seasonal Influenza Vaccine influenza vaccine - Human Influenza | Phase 3 | Completed | Research Institute for Biological Safety Problems | 2000 | 2017-09-18 | 2018-06-28 |
| Transmission of Influenza Virus From Asymptomatic Healthcare Workers and Inpatients in the Acute Care Hospital Setting Influenza - Human Influenza | Completed | University of Zurich | 700 | 2016-01-01 | 2017-10-31 | |
| Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults Recombinant Influenza Vaccine, Inactivated Influenza Vaccine - Human Influenza | Completed | Protein Sciences Corporation | 254648 | 2015-11-01 | 2017-10-12 | |
| A Study to Evaluate Safety and Immunogenicity of Trivalent Influenza Vaccine, Formulation 2015 Southern Hemisphere, When Administered to Healthy Adult Subjects. Aggripal® - Human Influenza | Phase 2 | Completed | Novartis | 126 | 2015-04-01 | 2015-10-19 |
| Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection for Children and Adolescents Vaccination with Fluval AB Novo suspension for injection, half dose of a single intramuscular dose (0.25 ml), Vaccination with Fluval AB Novo suspension for injection, single intramuscular dose (0.5 ml) - Human Influenza | Phase 3 | Completed | Fluart Innovative Vaccine Ltd, Hungary | 120 | 2014-10-01 | 2021-03-11 |
| Clinical Trial for the Evaluation of Three Regimens of Influenza Vaccination in Kidney Transplant Recipients Trivalent influenza vaccine (inactivated and fragmented). - Human Influenza | Phase 4 | Completed | Butantan Institute | 195 | 2014-04-01 | 2015-07-21 |
| Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above TIVf - Human Influenza | Phase 3 | Completed | Novartis Vaccines | 125 | 2013-08-01 | 2014-03-12 |
| Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvanted Influenza Study Vaccine in Adults Aged 18 Years and Above TIVc - Human Influenza | Phase 3 | Completed | Novartis Vaccines | 126 | 2013-08-01 | 2017-02-23 |
| Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and Above TIV - Human Influenza | Phase 2 | Completed | Novartis Vaccines | 126 | 2013-07-01 | 2014-03-12 |
| Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age aTIV - Human Influenza | Phase 2 | Completed | Novartis Vaccines | 63 | 2013-07-01 | 2014-03-26 |
| Panama and El Salvador Children's Oseltamivir Study Oseltamivir phosphate suspension, Placebo - Influenza, Human Influenza | Phase 4 | Terminated | Centers for Disease Control and Prevention | 721 | 2012-09-01 | 2014-07-01 |
| Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above Trivalent influenza virus vaccine (TIV) - Human Influenza | Phase 2 | Completed | Novartis Vaccines | 126 | 2012-07-01 | 2015-11-30 |
| Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects Adjuvanted Trivalent Influenza Virus Vaccine (aTIV) - Human Influenza | Phase 2 | Completed | Novartis Vaccines | 63 | 2012-07-01 | 2014-04-21 |
| Phase IV Clinical Trial of an Inactivated Influenza Split Vaccine Inactivated influenza split vaccine - Human Influenza | Phase 4 | Completed | Hualan Biological Engineering, Inc. | 6000 | 2011-11-01 | 2012-08-14 |
| Conventional Vaccine and Intradermal Vaccine Among HIV-infected Young Subjects Agripal, IDflu9μg, IDflu15μg - Human Influenza | Phase 4 | Completed | Korea University Guro Hospital | 88 | 2011-11-01 | 2015-03-25 |
| Study of Yili Mei Yi Tian Active Lactobacillus Drink to Improve Immunity and Digestive System Yili "Mei Yi Tian" active lactobacillus drink, recombined milk drink contains no lactobacillus - Immunization, Human Influenza | Not applicable | Completed | Inner Mongolia Yili Industrial Group Co., Ltd | 240 | 2011-08-01 | 2012-10-15 |
Showing 20 of 26. Sign in to see all of them.
Influenza, Human (26) · Common Cold (2) · Orthomyxoviridae Infections (2) · Respiratory Tract Infections (2) · Abdominal Pain (1) · Constipation (1) · Dyspepsia (1) · Enterovirus Infections (1) · Flatulence (1) · Respiratory Syncytial Virus Infections (1) · Virus Diseases (1)
Infections (26) · RNA Virus Infections (26) · Respiratory Tract Diseases (26) · Virus Diseases (25) · Orthomyxoviridae Infections (24) · Respiratory Tract Infections (24) · Picornaviridae Infections (3) · Mononegavirales Infections (1) · Neurologic Manifestations (1) · Pain (1) · Paramyxoviridae Infections (1) · Pathological Conditions, Signs and Symptoms (1) · Pneumovirus Infections (1) · Signs and Symptoms (1) · Signs and Symptoms, Digestive (1)
Influenza Vaccines (6) · Injections (2) · FluBlok (1) · Lactoferrin (1) · Oseltamivir (1) · Soaps (1) · Vaccination (1) · enisamium iodide (1) · fluarix (1) · vaxigrip (1)
Novartis Vaccines (7) · Fluart Innovative Vaccine Ltd, Hungary (2) · Hualan Biological Engineering, Inc. (2) · Inner Mongolia Yili Industrial Group Co., Ltd (2) · Butantan Institute (1) · Centers for Disease Control and Prevention (1) · Chinese Academy of Sciences (1) · Emergent BioSolutions (1) · Imperial College London (1) · International Centre for Diarrhoeal Disease Research, Bangladesh (1) · Joint Stock Company "Farmak" (1) · Korea University Guro Hospital (1) · Novartis (1) · Protein Sciences Corporation (1) · Research Institute for Biological Safety Problems (1)
Belgium (5) · China (5) · Brazil (2) · Germany (2) · United States (2) · Australia (1) · Bangladesh (1) · El Salvador (1) · Hungary (1) · Kazakhstan (1) · Panama (1) · Switzerland (1) · United Kingdom (1)
Ying An, Ph.D (2) · Alexander R Precioso, MD, PhD (1) · David Muir (1) · Donglian Cai (1) · Eduardo Azziz-Baumgartner, MD, MPH (1) · Ekatarina A. Okhapkina (1) · Fatimah S Dawood, MD (1) · Gengru Jiang (1) · George Fu Gao, Ph.D. (1) · Hee Jin Cheong, MD, PhD (1) · James McCarthy, MD (1) · Jorge Jara, MD (1) · Leiming Xu (1)
PMID 19954075, PMID 25037034, PMID 26066651, PMID 26431466, PMID 31113375, PMID 31153920, PMID 33215698, PMID 33239124, PMID 33558285, PMID 33988337, PMID 36715243, PMID 41785036